|
1
|
Palumbo A and Anderson K: Multiple
myeloma. N Engl J Med. 64:1046–1060. 2011. View Article : Google Scholar
|
|
2
|
Lorsbach RB, Hsi ED, Dogan A and Fend F:
Plasma cell myeloma and related neoplasms. Am J Clin Pathol.
136:168–182. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heerema-McKenney A, Waldron J, Hughes S,
Zhan F, Sawyer J, Barlogie B and Shaughnessy JD Jr: Clinical,
immunophenotypic, and genetic characterization of small
lymphocyte-like plasma cell myeloma: A potential mimic of mature
B-cell lymphoma. Am J Clin Pathol. 133:265–270. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bataille R, Jégo G, Robillard N,
Barillé-Nion S, Harousseau JL, Moreau P, Amiot M and
Pellat-Deceunynck C: The phenotype of normal, reactive and
malignant plasma cells. Identification of ‘many and multiple
myelomas’ and of new targets for myeloma therapy. Haematologica.
91:1234–1240. 2006.PubMed/NCBI
|
|
5
|
Lin P, Owens R, Tricot G and Wilson CS:
Flow cytometric immunophenotypic analysis of 306 cases of multiple
myeloma. Am J Clin Pathol. 121:482–488. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pellat-Deceunynck C, Barillé S, Jego G,
Puthier D, Robillard N, Pineau D, Rapp MJ, Harousseau JL, Amiot M
and Bataille R: The absence of CD56 (NCAM) on malignant plasma
cells is a hallmark of plasma cell leukemia and of a special subset
of multiple myeloma. Leukemia. 12:1977–1982. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sahara N, Takeshita A, Shigeno K, Fujisawa
S, Takeshita K, Naito K, Ihara M, Ono T, Tamashima S, Nara K, et
al: Clinicopathological and prognostic characteristics of
CD56-negative multiple myeloma. Br J Haematol. 117:882–885. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sahara N and Takeshita A: Prognostic
significance of surface markers expressed in multiple myeloma: CD56
and other antigens. Leuk Lymphoma. 45:61–65. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pozdnyakova O, Morgan EA, Li B, Shahsafaei
A and Dorfman DM: Patterns of expression of CD56 and CD117 on
neoplastic plasma cells and association with genetically distinct
subtypes of plasma cell myeloma. Leuk Lymphoma. 53:1905–1910. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Almeida J, Orfao A, Ocqueteau M, Mateo G,
Corral M, Caballero MD, Blade J, Moro MJ, Hernandez J and Miguel
San JF: High-sensitive immunophenotyping and DNA ploidy studies for
the investigation of minimal residual disease in multiple myeloma.
Br J Haematol. 107:121–131. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Robillard N, Wuillème S, Lodé L,
Magrangeas F, Minvielle S and Avet-Loiseau H: CD33 is expressed on
plasma cells of a significant number of myeloma patients, and may
represent a therapeutic target. Leukemia. 19:2021–2022. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sahara N, Ohnishi K, Ono T, Sugimoto Y,
Kobayashi M, Takeshita K, Shigeno K, Nakamura S, Naito K, Tamashima
S, et al: Clinicopathological and prognostic characteristics of
CD33-positive multiple myeloma. Eur J Haematol. 77:14–18. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rajkumar SV: Multiple myeloma: 2013 update
on diagnosis, risk-stratification, and management. Am J Hematol.
88:226–235. 2013. View Article : Google Scholar : PubMed/NCBI
|
